ACR Appropriateness Criteria® rectal cancer: Metastatic disease at presentation Journal Article


Authors: Goodman, K. A.; Milgrom, S. A.; Herman, J. M.; Abdel-Wahab, M.; Azad, N.; Blackstock, A. W.; Das, P.; Hong, T. S.; Jabbour, S. K.; Jones, W. E.; Konski, A. A.; Koong, A. C.; Kumar, R.; Rodriguez-Bigas, M.; Small, W.; Thomas, C. R.; Suh, W. W.
Article Title: ACR Appropriateness Criteria® rectal cancer: Metastatic disease at presentation
Abstract: The management of rectal cancer in patients with metastatic disease at presentation is highly variable. There are no phase III trials addressing therapeutic approaches, and the optimal sequencing of chemotherapy, radiation therapy, and surgery remains unresolved. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial. Omitting chemoradiation may not be appropriate in all stage IV patients, particularly those with symptomatic primary tumors. Moreover, out-comes in this setting are vastly different, as some treatments carry the potential for cure in selected patients, while others are purely palliative. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application, by the panel, of a well-established consensus methodology (Modified Delphi) to rate the appropriateness of imaging and treatment procedures. In instances in which evidence is lacking or not definitive, expert opinion may be used as the basis for recommending imaging or treatment.
Keywords: resection; radiofrequency ablation; long-term survival; colorectal liver metastases; radiation-therapy; phase-iii trial; 1st-line treatment; 10-year experience; systemic chemotherapy; hepatic; infusional fluorouracil
Journal Title: Oncology (Norwalk)
Volume: 28
Issue: 10
ISSN: 0890-9091
Publisher: C M P Medica LLC * The Oncology Group  
Date Published: 2014-10-15
Start Page: 867
End Page: 878
Language: English
ACCESSION: WOS:000344133200008
PROVIDER: wos
PUBMED: 25323613
Notes: Article -- Source: Wos
Citation Impact
MSK Authors
  1. Karyn A Goodman
    257 Goodman
  2. Sarah Allison Milgrom
    22 Milgrom